Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · September 05, 2024

Efficacy of CDK4/6 Inhibitors Plus Endocrine Therapy vs Placebo Plus Endocrine Therapy for HR+/HER2− Advanced Breast Cancer

BMC Cancer

 

Additional Info

BMC Cancer
CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis
BMC Cancer 2024 Aug 21;24(1)1031, C Luo, K Yu, X Luo, T Lian, X Liu, W Xu, Z Jin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading